Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 68622P109 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Nextech Crossover I GP S.a r.l.
13G/A
|
8.4% |
8/14/2025
Event 6/30/2025
|
||
| Nextech Crossover I GP S.a. r.l. | 8.4% | |||
| Nextech Crossover I SCSp | 8.4% | |||
| Ian Charoub | 8.4% | |||
| Costas Constantinides | 8.4% | |||
| Rocco Sgobbo | 8.4% | |||
|
Viking Global Investors LP
13G/A
|
7.8% |
5/15/2026
Event 3/31/2026
|
||
| Viking Global Investors LP | 7.8% | |||
| Viking Global Opportunities Parent GP LLC | 7.8% | |||
| Viking Global Opportunities GP LLC | 5.0% | |||
| Viking Global Opportunities Portfolio GP LLC | 5.0% | |||
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 5.0% | |||
| Viking Global Opportunities Drawdown GP LLC | 2.8% | |||
| Viking Global Opportunities Drawdown Portfolio GP LLC | 2.8% | |||
| Viking Global Opportunities Drawdown (Aggregator) LP | 2.8% | |||
| Halvorsen Ole Andreas | 7.8% | |||
| Shabet Rose Sharon | 7.8% | |||
|
EcoR1 Capital, LLC
13G
|
6.9% |
8/5/2025
Event 7/29/2025
|
||
| EcoR1 Capital, LLC | 6.9% | |||
| Oleg Nodelman | 6.9% | |||
| EcoR1 Capital Fund Qualified, L.P. | 6.5% | |||
| BlackRock, Inc. 13G | 5.6% |
1/21/2026
Event 12/31/2025
|
||
| Price T Rowe Associates Inc /MD/ 13G | 5.4% |
5/15/2026
Event 3/31/2026
|
||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (8) | ||||
|
SR One Capital Management, LLC
13D/A
|
4.8% |
8/14/2025
Event 8/12/2025
|
||
| SR One Capital Management, LLC | 4.8% | |||
| SR One Capital Opportunities Fund I, LP | 2.5% | |||
| SR One Capital Opportunities Partners I, LP | 2.5% | |||
| Amzl, LP | 1.6% | |||
| SR One Capital SMA Partners, LP | 1.6% | |||
| SR One Capital Fund II Aggregator, LP | 0.7% | |||
| SR One Capital Partners II, LP | 0.7% | |||
| Simeon George | 4.8% | |||
|
Alkeon Capital Management LLC
13G/A
|
4.6% |
11/13/2025
Event 9/30/2025
|
||
| Alkeon Capital Management LLC | 4.6% | |||
| Panayotis D. Sparaggis | 4.6% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
4.2% |
5/15/2026
Event 3/31/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 4.2% | |||
| VHCP Co-Investment Holdings III, LLC | 4.2% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 4.2% | |||
| VHCP Management III, LLC | 4.2% | |||
| VHCP Management EG, LLC | 4.2% | |||
| Nimish Shah | 4.2% | |||
| Bong Y. Koh | 4.2% | |||
|
Column Group II, LP
13G/A
|
3.7% |
11/17/2025
Event 9/30/2025
|
||
| The Column Group II, LP | 3.6% | |||
| The Column Group II GP, LP | 3.6% | |||
| David V Goeddel | 3.7% | |||
| Peter Svennilson | 3.7% | |||
|
FMR LLC
13G/A
|
3.5% |
2/12/2025
Event 12/31/2024
|
||
| FMR LLC | 3.5% | |||
| Abigail P. Johnson | 3.5% | |||
| Pfizer Inc 13G/A | 3.3% |
5/12/2026
Event 3/31/2026
|
||
|
Frazier Life Sciences Public Fund, L.P.
13G/A
|
2.0% |
5/15/2025
Event 3/31/2025
|
||
| Frazier Life Sciences Public Fund, L.P. | 0.9% | |||
| FHMLSP, L.P. | 0.9% | |||
| FHMLSP, L.L.C. | 0.9% | |||
| Frazier Life Sciences Public Overage Fund, L.P. | 0.6% | |||
| FHMLSP Overage, L.P. | 0.6% | |||
| FHMLSP Overage, L.L.C. | 0.6% | |||
| Frazier Life Sciences X, L.P. | 0.2% | |||
| FHMLS X, L.P. | 0.2% | |||
| FHMLS X, L.L.C. | 0.2% | |||
| Frazier Life Sciences XI, L.P. | 0.4% | |||
| FHMLS XI, L.P. | 0.4% | |||
| FHMLS XI, L.L.C. | 0.4% | |||
| James N. Topper | 2.0% | |||
| Patrick J. Heron | 2.0% | |||
| Albert Cha | 1.4% | |||
| James Brush | 1.4% | |||
| Daniel Estes | 0.4% | |||
|
Point72 Asset Management, L.P.
13G/A
|
0% |
5/15/2026
Event 3/31/2026
|
||
| Point72 Asset Management, L.P. | 0% | |||
| Point72 Capital Advisors, Inc. | 0% | |||
| Steven A. Cohen | 0% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 7 | 24.6 k | $300 k |
| 2026 Q2 | 187 | 124 M | $1.41 B |
| 2026 Q1 | 185 | 119 M | $1.51 B |
| 2025 Q4 | 169 | 120 M | $980 M |
| 2025 Q3 | 157 | 108 M | $1.29 B |
| 2025 Q2 | 148 | 93.5 M | $949 M |
| 2025 Q1 | 147 | 79.2 M | $442 M |
| 2024 Q4 | 136 | 75.8 M | $612 M |
| 2024 Q3 | 126 | 69.9 M | $715 M |
| 2024 Q2 | 116 | 68.1 M | $482 M |
| 2024 Q1 | 120 | 64.6 M | $888 M |
| 2023 Q4 | 99 | 51.2 M | $471 M |
| 2023 Q3 | 96 | 49.0 M | $297 M |
| 2023 Q2 | 89 | 45.5 M | $353 M |
| 2023 Q1 | 76 | 33.1 M | $189 M |
| 2022 Q4 | 70 | 32.5 M | $193 M |
| 2022 Q3 | 81 | 32.7 M | $105 M |
| 2022 Q2 | 88 | 32.8 M | $147 M |
| 2022 Q1 | 105 | 34.0 M | $182 M |
| 2021 Q4 | 82 | 34.9 M | $513 M |
| 2021 Q3 | 83 | 36.4 M | $762 M |
| 2021 Q2 | 79 | 36.1 M | $639 M |
| 2021 Q1 | 85 | 35.7 M | $874 M |
| 2020 Q4 | 77 | 32.6 M | $1.10 B |
| 2020 Q3 | 56 | 22.2 M | $553 M |
| 2020 Q2 | 67 | 21.5 M | $722 M |